These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 21948815)

  • 1. Optimal prostate-specific antigen screening interval for prostate cancer.
    Kobayashi D; Takahashi O; Fukui T; Glasziou PP
    Ann Oncol; 2012 May; 23(5):1250-1253. PubMed ID: 21948815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate carcinoma detection and increased prostate-specific antigen levels after 4 years in Dutch and Japanese males who had no evidence of disease at initial screening.
    Ito K; Raaijmakers R; Roobol M; Wildhagen M; Yamanaka H; Schröder FH
    Cancer; 2005 Jan; 103(2):242-50. PubMed ID: 15578715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal screening interval for men with low baseline prostate-specific antigen levels (≤1.0 ng/mL) in a prostate cancer screening program.
    Urata S; Kitagawa Y; Matsuyama S; Naito R; Yasuda K; Mizokami A; Namiki M
    World J Urol; 2017 Apr; 35(4):579-586. PubMed ID: 27421271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cumulative probability of PSA increase above 4.0 NG/ML in population-based screening for prostate cancer.
    Ito K; Yamamoto T; Ohi M; Takechi H; Kurokawa K; Suzuki K; Yamanaka H
    Int J Cancer; 2004 Apr; 109(3):455-60. PubMed ID: 14961587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study.
    Carlsson S; Assel M; Sjoberg D; Ulmert D; Hugosson J; Lilja H; Vickers A
    BMJ; 2014 Mar; 348():g2296. PubMed ID: 24682399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Annual PSA tests are not necessary for men with a PSA level below 2 ng/mL: findings of the Imari prostate cancer screening program.
    Uozumi J; Tokuda Y; Fujiyama C; Takagi N; Meiri H; Kuratomi K; Nakamura K; Ichigi Y; Yoshinaga H; Kinoshita N; Masaki Z
    Int J Urol; 2002 Jun; 9(6):334-9. PubMed ID: 12110098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Possibility of re-screening intervals of more than one year in men with PSA levels of 4.0 ng/ml or less.
    Ito K; Yamamoto T; Ohi M; Takechi H; Kurokawa K; Suzuki K; Yamanaka H
    Prostate; 2003 Sep; 57(1):8-13. PubMed ID: 12886518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).
    Roobol MJ; Roobol DW; Schröder FH
    Urology; 2005 Feb; 65(2):343-6. PubMed ID: 15708050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PSA-based screening for prostate cancer in asymptomatic younger males: pilot study in blood donors.
    Reissigl A; Pointner J; Horninger W; Strasser H; Mayersbach P; Klocker H; Schönitzer D; Bartsch G
    Prostate; 1997 Jan; 30(1):20-5. PubMed ID: 9018331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of race and baseline PSA on longitudinal PSA.
    McGreevy K; Rodgers K; Lipsitz S; Bissada N; Hoel D
    Int J Cancer; 2006 Apr; 118(7):1773-6. PubMed ID: 16231314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate cancer screening practices in a large, integrated health system: 2007-2014.
    Misra-Hebert AD; Hu B; Klein EA; Stephenson A; Taksler GB; Kattan MW; Rothberg MB
    BJU Int; 2017 Aug; 120(2):257-264. PubMed ID: 28139034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable.
    Hugosson J; Aus G; Lilja H; Lodding P; Pihl CG; Pileblad E
    J Urol; 2003 May; 169(5):1720-3. PubMed ID: 12686817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Baseline Prostate-Specific Antigen Level With Long-term Diagnosis of Clinically Significant Prostate Cancer Among Patients Aged 55 to 60 Years: A Secondary Analysis of a Cohort in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
    Kovac E; Carlsson SV; Lilja H; Hugosson J; Kattan MW; Holmberg E; Stephenson AJ
    JAMA Netw Open; 2020 Jan; 3(1):e1919284. PubMed ID: 31940039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer.
    Carter HB; Epstein JI; Chan DW; Fozard JL; Pearson JD
    JAMA; 1997 May; 277(18):1456-60. PubMed ID: 9145718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate-specific antigen testing of older men.
    Carter HB; Landis PK; Metter EJ; Fleisher LA; Pearson JD
    J Natl Cancer Inst; 1999 Oct; 91(20):1733-7. PubMed ID: 10528023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of prostate-specific antigen velocity in screening for prostate cancer.
    Ito K; Yamamoto T; Ohi M; Kubota Y; Fukabori Y; Kurokawa K; Suzuki K; Yamanaka H
    Int J Urol; 2002 Jun; 9(6):316-21. PubMed ID: 12110095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate cancer screening in Tyrol, Austria: experience and results.
    Horninger W; Reissigl A; Rogatsch H; Volgger H; Studen M; Klocker H; Bartsch G
    Eur Urol; 1999; 35(5-6):523-38. PubMed ID: 10325519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of age-specific reference range of prostate-specific antigen for Japanese men older than 60 years in mass screening for prostate cancer.
    Ito K; Yamamoto T; Kubota Y; Suzuki K; Fukabori Y; Kurokawa K; Yamanaka H
    Urology; 2000 Aug; 56(2):278-82. PubMed ID: 10925094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate cancer screening in the Tyrol, Austria: experience and results.
    Horninger W; Reissigl A; Rogatsch H; Volgger H; Studen M; Klocker H; Bartsch G
    Eur J Cancer; 2000 Jun; 36(10):1322-35. PubMed ID: 10882875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic value of percent free prostate-specific antigen: retrospective analysis of a population-based screening study with emphasis on men with PSA levels less than 3.0 ng/mL.
    Törnblom M; Norming U; Adolfsson J; Becker C; Abrahamsson PA; Lilja H; Gustafsson O
    Urology; 1999 May; 53(5):945-50. PubMed ID: 10223488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.